Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: Evaluation of therapeutic ratios

Behavioural Pharmacology

Volumn 24, Issue 7, 2013, Pages 628-632

  Hubbard, David ^a   Hacksell, Uli ^a   McFarland, Krista ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

6 hydroxydopamine lesion; Animal model; Parkinson's disease psychosis; Rat; Serotonin, substantia nigra; Therapeutic index

Indexed keywords

APOMORPHINE; CLOZAPINE; OXIDOPAMINE; PIMAVANSERIN; QUETIAPINE; AMPHETAMINE; ANTIPARKINSON AGENT; DOPAMINE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPSYCHOTIC EFFECT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PSYCHOSIS; RAT; SEDATION; SUBSTANTIA NIGRA; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; METABOLISM; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PSYCHOTIC DISORDERS; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANIMALS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; CLOZAPINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PARKINSONIAN DISORDERS; PIPERIDINES; PSYCHOTIC DISORDERS; QUETIAPINE FUMARATE; RATS; RATS, SPRAGUE-DAWLEY; UREA;

EID: 84888298552     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283656db6     Document Type: Article

References (22)

1. Balcioglu A, Zhang K, Tarazi FI (2003). Dopamine depletion abolishes apomorphine-and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: A microdialysis study. Neuroscience 119:1045-1053.
2. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH (2010). Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 67:416-421.
3. Boulet S, Mounayar S, Poupard A, Bertrand A, Jan C, Pessiglione M, et al. (2008). Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J Neurosci 28: 9575-9584.
4. Bruno JP, Jackson D, Zigmond MJ, Stricker EM (1987). Effect of dopaminedepleting brain lesions in rat pups: role of striatal serotonergic neurons in behavior. Behav Neurosci 101:806-811.
5. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ (1998). Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinsons disease neocortex. Ann N Y Acad Sci 861:288-289.
6. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Bahr D, Dhall R (2013). Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinsons disease psychosis (ACP-103-020). Mov Disord 28.
7. Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G (2010). A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 67:996-1001.
8. Fenelon G (2008). Psychosis in Parkinsons disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13:18-25.
9. Goetz CG, Stebbins GT (1993). Risk factors for nursing home placement in advanced Parkinsons disease. Neurology 43:2227-2229.
10. Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, et al. (2010). Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 25:1399-1408.
11. McFarland K, Price DL, Bonhaus DW (2011). Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinsons disease. Behav Pharmacol 22:681-692.
12. Ondo WG,Tintner R, Voung KD, Lai D, Ringholz G (2005). Double-blind, placebocontrolled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinsons disease. Mov Disord 20:958-963.
13. Paxinos G,Watson C (1998). The Rat Brain in Stereotaxic Coordinates. 4th edn New York: Academic Press.
14. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007). Effect of quetiapine in psychotic Parkinsons disease patients: A double-blind labeled study of 3 months duration. Mov Disord 22:313-318.
15. Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL (1998). Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 245:151-154.
16. Shotbolt P, Samuel M, Fox C, David AS (2009). A randomized controlled trial of quetiapine for psychosis in Parkinsons disease. Neuropsychiatr Dis Treat 5:327-332.
17. The French Clozapine Parkinson Study Group (1999). Clozapine in drug-induced psychosis in Parkinsons disease. Lancet 353:2041-2042.
18. The Parkinson Study Group (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinsons disease. N Engl J Med 340: 757-763.
19. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, et al. (2006). Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N- (1-methylpiperidin-4-yl)-N0-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2 : 1) (ACP-103), a novel 5-hydroxytryptamine( 2A) receptor inverse agonist. J Pharmacol Exp Ther 317:910-918.
20. Zahodne LB, Fernandez HH (2008). Pathophysiology and treatment of psychosis in Parkinsons disease: A review. Drugs Aging 25:665-682.
21. Zhang X, Andren PE, Svenningsson P (2007). Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinsons disease model. Physiol Behav 92:29-33.
22. Zhou FC, Bledsoe S, Murphy J (1991). Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 556:108-116.